174 related articles for article (PubMed ID: 7574528)
1. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
Allendoerfer R; Loebenberg D; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 1995 Jun; 39(6):1345-8. PubMed ID: 7574528
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.
Denning DW; Hall L; Jackson M; Hollis S
Antimicrob Agents Chemother; 1995 Aug; 39(8):1809-14. PubMed ID: 7486923
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.
Chandrasekar PH; Cutright JL; Manavathu EK
Clin Microbiol Infect; 2004 Oct; 10(10):925-8. PubMed ID: 15373889
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis.
Chiang LY; Ejzykowicz DE; Tian ZQ; Katz L; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3464-6. PubMed ID: 17005833
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.
Oakley KL; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1997 Jul; 41(7):1504-7. PubMed ID: 9210674
[TBL] [Abstract][Full Text] [Related]
8. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.
Dannaoui E; Borel E; Persat F; Monier MF; Piens MA; Network E
J Med Microbiol; 1999 Dec; 48(12):1087-1093. PubMed ID: 10591162
[TBL] [Abstract][Full Text] [Related]
9. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.
Kirkpatrick WR; McAtee RK; Fothergill AW; Loebenberg D; Rinaldi MG; Patterson TF
Antimicrob Agents Chemother; 2000 Mar; 44(3):780-2. PubMed ID: 10681359
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
13. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone.
Manavathu EK; Dimmock JR; Vashishtha SC; Cutright J; Chandrasekar PH
J Antimicrob Chemother; 1998 Nov; 42(5):585-90. PubMed ID: 9848441
[TBL] [Abstract][Full Text] [Related]
14. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Warn PA; Sharp A; Morrissey G; Denning DW
Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
[TBL] [Abstract][Full Text] [Related]
15. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis.
Le Conte P; Joly V; Saint-Julien L; Gillardin JM; Carbon C; Yeni P
Am Rev Respir Dis; 1992 Feb; 145(2 Pt 1):424-9. PubMed ID: 1310577
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Matsumoto S; Wakai Y; Nakai T; Hatano K; Ushitani T; Ikeda F; Tawara S; Goto T; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):619-21. PubMed ID: 10681328
[TBL] [Abstract][Full Text] [Related]
17. Multi-azole resistance in Aspergillus fumigatus.
Howard SJ; Webster I; Moore CB; Gardiner RE; Park S; Perlin DS; Denning DW
Int J Antimicrob Agents; 2006 Nov; 28(5):450-3. PubMed ID: 17034993
[TBL] [Abstract][Full Text] [Related]
18. Acquired itraconazole resistance in Aspergillus fumigatus.
Dannaoui E; Borel E; Monier MF; Piens MA; Picot S; Persat F
J Antimicrob Chemother; 2001 Mar; 47(3):333-40. PubMed ID: 11222566
[TBL] [Abstract][Full Text] [Related]
19. Standardization of an experimental murine model of invasive pulmonary aspergillosis.
Sheppard DC; Graybill JR; Najvar LK; Chiang LY; Doedt T; Kirkpatrick WR; Bocanegra R; Vallor AC; Patterson TF; Filler SG
Antimicrob Agents Chemother; 2006 Oct; 50(10):3501-3. PubMed ID: 17005844
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
